HarshrajLeuvaMD(He/Him)

Oncology • Bellevue, NE

Genitourinary Oncology

Assistant Professor

Join to view full profile

Dr. Leuva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Leuva's full profile

Already have an account?

Office
2510 Bellevue Medical Center Dr
Ste 250
Bellevue, NE 68123
Phone+1 402-559-8013

Summary

Dr. Harshraj Leuva is an oncologist in Bellevue, NE and is affiliated with multiple hospitals in the area, including James J. Peters Veterans Affairs Medical Center and Nebraska Medicine - Nebraska Medical Center.. He specializes in genitourinary oncology and is experienced in prostate cancer and medical oncology. He has 7 publications and over 500 citations.

Education & Training

SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2019 - 2022
Icahn School of Medicine at Mount Sinai (Bronx)Chief Residency, Internal Medicine, 2018 - 2019
Icahn School of Medicine at Mount Sinai (Bronx)Residency, Internal Medicine, 2015 - 2018
OtherClass of 2010

Certifications & Licensure

NE State Medical License 2022 - 2026
NY State Medical License 2018 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Young Investigator Award American Society of Clinical Oncology (ASCO), 2021

Publications & Presentations

PubMed

Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses.
Harshraj Leuva, Mengxi Zhou, Nader Jamaleddine, Mina Meseha, Izak Faiena
Ebiomedicine. 2024-09-01
1 citations
Talazoparib in Patients With Solid Tumors With/Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
Gordan Srkalovic, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn
JCO Precision Oncology. 2024-06-01
Assessment of PSA responses and changes in the rate of tumor growth (g-rate) with immune checkpoint inhibitors in US Veterans with prostate cancer.
Harshraj Leuva, George Moran, Nader Jamaleddine, Mina Meseha, Mengxi Zhou
Seminars in Oncology. 2024-05-11

Lectures

The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Admini...
2019 ASCO Annual Meeting - 6/1/2019
A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abirateron...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018